Using patient-level decision modeling to improve use of treatments for alcohol use disorder

使用患者层面的决策模型来改善酒精使用障碍治疗的使用

• 批准号: 10712474
• 负责人: Phuc Le
• 金额: $ 68.37万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-15 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712474
• 关键词: Abstinence; Accounting; Acute; Adult; Affect; Alcohol abuse; Alcohol consumption; Alcohol dependence; Alcoholic Liver Diseases; Alcoholics Anonymous; Alcohols; American; American Psychiatric Association; Baclofen; Behavior Therapy; COVID-19 pandemic; Calibration; Caring; Cessation of life; Chronic Disease; Cognitive Therapy; Computer Simulation; Data; Decision Aid; Decision Modeling; Development; Disease model; Disulfiram; Effectiveness; Feedback; Head; Health; Health Benefit; Heavy Drinking; Injectable; Intervention; Interview; Life; Literature; Liver diseases; Mathematical Model Simulation; Medical; Mission; Modeling; Naltrexone; National Institute on Alcohol Abuse and Alcoholism; Natural History; Oral; Organ; Outcome; Patients; Persons; Pharmaceutical Preparations; Pharmacotherapy; Physicians; Policy Maker; Prevalence; Provider; Public Health; Quality of life; Randomized, Controlled Trials; Recommendation; Recovery; Reporting; Research; Selection for Treatments; Severities; Structure; Support Groups; System; Time; Treatment Effectiveness; United States Food and Drug Administration; acamprosate; alcohol abuse therapy; alcohol measurement; alcohol use disorder; behavioral study; brief intervention; comparative effectiveness; compare effectiveness; cost; design; drinking; drinking behavior; follow-up; gabapentin; improved; innovation; liver transplantation; models and simulation; motivational enhancement therapy; optimal treatments; prevent; programs; psychosocial; shared decision making; success; tool; topiramate; treatment comparison; trial comparing

Project Summary Alcohol use disorder (AUD), previously alcohol abuse and dependence, is a significant public health problem. In the US, excessive alcohol use is responsible for 93,000 deaths and 2.7 million years of potential life lost, at a cost of $250 billion annually. In 2012-13, the 12-month and life-time prevalence of AUD in US adults was 14% and 29%, respectively, increasing by more than 40% from a decade earlier. Since the Covid-19 pandemic, alcohol consumption has increased even more. Excessive alcohol consumption affects various bodily organs, leading to many health consequences. Fortunately, AUD is more treatable than commonly believed. Cognitive behavioral therapy, brief interventions, and motivational enhancement therapy are the most widely studied behavioral interventions and are similarly efficacious, while Alcoholics Anonymous (AA) is the most sought out mutual support group. Pharmacotherapy can be combined with behavioral interventions to increase success. However, treatments for AUD are underutilized. The misconception among patients and physicians that treatment is ineffective is an important obstacle to use. Another is the common view that treatment success requires total abstinence. In reality, recovery from AUD can include some heavy drinking, and AUD treatment can be effective. Expressing treatment effectiveness into long-term health benefits could help convince physicians to offer treatment and encourage patients to use it. However, randomized controlled trials (RCTs) alone cannot provide this information because they do not measure long-term health outcomes, nor do they compare all treatments head-to-head, making it difficult to choose among them. Simulation modeling offers a comprehensive approach to comparing treatments, but none of existing AUD models were designed to assess all treatments. We designed a decision aid (DA) describing treatment options, but it does not yet include estimates of long-term benefits due to lack of such data at the time of development. Project objective: To develop, validate, and apply a computer simulation model to inform policy makers, physicians, and patients of the lifetime benefit of treatments for AUD. Aim 1: Develop and validate a microsimulation model of the natural history of alcohol-associated complications accounting for the change in drinking behaviors and AUD status over time. Aim 2: Assess the comparative effectiveness of AUD treatments. Aim 3: Incorporate patient and provider feedback to assess the clarity, content, and acceptability of augmenting an existing DA with comparative effectiveness data. Impact: Our model will offer a better understanding of the expected benefit of AUD treatments and provide an innovative approach to decision modeling and treatment selection. By incorporating long-term effectiveness data into an existing DA, our study will provide physicians and patients with valuable evidence and a tool to support selection of optimal treatments, thereby helping to close the treatment gap. Ultimately, our project will address NIAAA’s research missions while improving the quality of life for tens of millions of US adults suffering from AUD.

项目总结